No abstract

No abstract

Background and aim: Polycystic ovarian syndrome is a common endocrine disorder in reproductive age, with unknown etiology and a variable clinical presentation. Recognizing polycystic ovary syndrome in women presenting with oligo-ovulation and hyperandrogenism offers an important opportunity to begin a life-long conversation about prevention and treatment of a condition that has a multi-system impact on affected women. Recognition offers the chance for providers and patients to engage in discussions about prevention and early treatment of metabolic derangements. This review aims to review the polycystic ovarian syndrome and the approach to the metabolic complications such as insulin resistance and associated hyperinsulinemia.

EditorialPolycystic ovary syndrome (PCOS) is one of the most common ovaries but no signs of androgen excess. It is unclear whether endocrine disorders in women, affecting 5% to 10% of reproductive aged women. It is estimated that the healthcare-related economic sequelae as 'classic' PCOS characterized by androgen excess and burden of PCOS surpasses $US4 billion per year in the US. Women with PCOS experience a range of symptoms and signs of phenotypes included under the diagnosis of PCOS will diminish such as menstrual cycle disturbances, clinical or biochemical signs of androgen excess, and obesity. Early diagnosis and management defect in PCOS can help decrease the risk of associated reproductive, metabolic, and cardiovascular abnormalities. Recognition of the common dermatologic manifestations of PCOS (hirsutism, acne vulgaris, and androgenetic alopecia) may be essential to accurate diagnosis of the syndrome.

INTRODUÇÃO A lombalgia aguda é um motivo de consulta frequente nos cuidados de saúde primários (CSP). 1 Acomete cerca de 70 a 80% da população nalgum período da sua vida, constituindo uma das principais causas de dor crónica e de absentismo laboral. 2-3 Em cerca de 85% dos indivíduos não se identifica nenhuma patologia específica, pelo